Showing 1541-1550 of 1774 results for "".
- Pixium Vision Announces the Publication of Peer-Reviewed Clinical Data of the Prima System in Dry AMDhttps://modernod.com/news/pixium-vision-announces-the-publication-of-peer-reviewed-clinical-data-of-the-prima-system-in-dry-amd-i/2481167/Pixium Vision announced the publication of a paper in the Journal of Neural Engineering outlining further data from its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision, implanted i
- Harrow Announces FDA Approval of Iheezo for Ocular Surface Anesthesiahttps://modernod.com/news/harrow-announces-fda-approval-of-iheezo-for-ocular-surface-anesthesia/2481122/Harrow and Sintetica SA jointly announced the FDA approval of Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Iheezo is a sterile, single-patient‑use, physician‑administered, ophthalmic gel preparation, containing no preservatives, that i
- Glaukos Announces More Than 1 Million iStent Devices Implanted Worldwidehttps://modernod.com/news/glaukos-announces-more-than-1-million-istent-devices-implanted-worldwide/2481064/Glaukos announced that it has reached a milestone with its iStent family of technologies having now been implanted in more than 1 million procedures worldwide. “One million iStents implanted is a tremendous accomplishment and I’m grate
- Haag-Streit to Host 4th Annuel ‘Slit Lamp Imaging Competition’https://modernod.com/news/haag-streit-launches-4th-slit-lamp-imaging-competition/2480876/Haag-Streit announced the launch the "Slit Lamp Imaging Competition 2022." Following successful competitions held in 2019, 2020 and 2021, the competition gives eye care professionals across the globe an opportunity to showcase their slit lamp imaging skills. Judging criteria will i
- Verana Health Report Shows a More Than 80% Glaucoma Surgery Uptake Over 8-Year Periodhttps://modernod.com/news/verana-health-unveils-annual-ophthalmic-industry-report-that-shows-a-more-than-80-glaucoma-surgery-uptake-over-8-year-period-1/2480818/Verana Health announced the release of its American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Industry Report for 2021 at the ASCRS annual meeting. The report provides 8 years of detailed ophthalmic insights generated through analysis of the data contained i
- Shamir Announces Changes in Executive Leadershiphttps://modernod.com/news/shamir-announces-changes-in-executive-leadership/2480772/Shamir Insight announced that effective April 1, 2022, Pierson Ball, the company’s Director of Business and Strategic Development has been appointed as the new Vice President of Sales. Mr. Ball joined Shamir in 2007. “I am proud to have been part of the development and
- Bausch + Lomb Will Present New Scientific Data During the ASCRS Annual Meetinghttps://modernod.com/news/bausch-lomb-will-present-new-scientific-data-during-the-ascrs-annual-meeting/2480769/Bausch + Lomb announced the presentation of 10 podium presentations and two poster presentations during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place from April 22-26, 2022 in Washington, DC. The presentations will i
- Recipients of the 2022 Prevent Blindness Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Award Announcedhttps://modernod.com/news/recipients-of-the-2022-prevent-blindness-jenny-pomeroy-award-for-excellence-in-vision-and-public-health-and-rising-visionary-award-announced/2480762/Prevent Blindness has announced the recipient of the 2022 Jenny Pomeroy Award for Excellence in Vision and Public Health as VOSH/International (V/I). Additionally, Prevent Blindness has announced the co-recipients of the third annual “Rising Visionary Award” as Marissa K. Sh
- Ocuphire Meets Endpoints in Phase 3 MIRA-3 Trial Evaluating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-announces-positive-topline-results-from-mira-3-phase-3-fda-registration-trial-for-nyxol-in-the-reversal-of-mydriasis/2480730/Ocuphire Pharma announced positive topline results in the MIRA-3 trial, the company’s second phase 3 registration trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis (dilation of pupil). Ocuphire announced positive results from i
- Visus Therapeutics Initiates Phase 3 Pivotal Trials of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-initiates-phase-3-pivotal-trials-of-brimochol-pf-for-the-treatment-of-presbyopia/2480710/Visus Therapeutics announced the launch of the first of two pivotal phase 3 trials (BRIO-I and BRIO-II) for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. The initiation of the BRIO trials follows compelling topline data from th